Angiodynamics Inc
Current role
ANGO
Laura Piccinini
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Laura Piccinini
The proxy statement of Angiodynamics Inc reports total compensation of $1,608,687 for Laura Piccinini in fiscal 2026, including a base salary of $470,563. Disclosed compensation is on record for 5 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Angiodynamics Inc (ANGO)
Proxy statement
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Angiodynamics Inc
Other people whose current roles at this company are on record from its filings.
- Eric Honroth CEO, Board Member
- Former EVP CFO
- Stephen A. Trowbridge CFO
- Dennis Meteny Board Member
- Eileen O. Auen Board Member
- James Clemmer Board Member
- Jan Stern Reed Board Member
- Karen A. Licitra Board Member
- Lorinda A. Burgess Board Member
- Lorinda Burgess Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2026 | Angiodynamics Inc (ANGO) | SVP & GM, Cardiovascular and International | $470,563 | $1,608,687 |
| 2025 | Angiodynamics Inc (ANGO) | SVP & GM, Cardiovascular and International | $410,056 | $1,369,426 |
| 2024 | Angiodynamics Inc (ANGO) | SVP & GM, Cardiovascular and International | $401,282 | $1,229,380 |
| 2023 | Angiodynamics Inc (ANGO) | SVP & GM, Cardiovascular and International | $334,378 | $843,436 |
| 2022 | Angiodynamics Inc (ANGO) | SVP & GM, International Stock Awards: The stock awards column represents aggregate grant date fair value of restricted stock unit awards and performance share awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation - Stock Compensation. Accordingly, the grant date fair value of restricted stock units was determined by multiplying the number of restricted stock units by the closing stock price on the date of grant, while the grant date fair value of performance share awards was determined using a Monte Carlo simulation. The assumptions used in the valuation of stock-based awards are discussed in Note 14 to our Audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2023. The table below shows the grant date fair value of the performance share awards included in the stock awards column for each year, and the maximum grant date value assuming that the highest level of performance conditions was achieved: | $355,679 | $1,628,976 |
Recent activity
No call appearances or filed executive changes recorded yet.